Viewing Study NCT01891968


Ignite Creation Date: 2025-12-24 @ 5:50 PM
Ignite Modification Date: 2026-02-22 @ 9:38 AM
Study NCT ID: NCT01891968
Status: COMPLETED
Last Update Posted: 2018-04-23
First Post: 2013-06-28
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation
Sponsor: M.D. Anderson Cancer Center
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Leukemia View
None Myelodysplastic syndrome View
None MDS View
None Low or intermediate-1 View
None Bortezomib View
None Velcade View
None LDP-341 View
None MLN341 View
None PS-341 View